MEDIA & PRESS UPDATES

TAVOTEK LAUNCHING FIRST-IN-HUMAN STUDY OF 3 ASSETS IN 2022

April 7, 2022

(LOWER GWYNEDD, Pennsylvania, April 5, 2022)  Tavotek Biotherapeutics announced today that its first pipeline biologic asset, TAVO103A, had been successfully dosed in two human subjects in the ICON Phase 1 Clinical Trial Center in Salt Lake City, Utah.  TAVO103A is a best-in-class human monoclonal antibody developed for chronic inflammation.  This study, termed TAVO103A-0001, is a double-blind, randomized, placebo-controlled Phase 1 evaluation of the safety, tolerability, immunogenicity, and PK/PD of TAVO103A in human volunteer subjects.  The US IND was filed in late December 2021 and was approved by the FDA in January 2022.